PinnyPeptide

ARA-290 (Cibinetide) vs B7-33

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ARA-290 (Cibinetide)

Healing & Recovery

Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects.

Peptide B

B7-33

Muscle Growth

Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity.

Typical vial

8 mg

Typical dose

2,000-8,000 mcg

Half-life

~2 minutes (plasma); longer functional duration via receptor binding

FDA status

Not FDA approved. In clinical development by Araim Pharmaceu…

Typical vial

2 mg

Typical dose

1000-2000 mcg

Half-life

~2-3 hours

FDA status

Not FDA approved.

ARA-290 (Cibinetide) effects

  • Activates the innate repair receptor (IRR / EpoR-βcR heterodimer)
  • Reduces tissue inflammation in injury models
  • Promotes axonal regeneration in small-fiber neuropathy
  • Does NOT raise hemoglobin or platelet count
  • Tissue-protective in ischemia-reperfusion models

B7-33 effects

  • Anti-fibrotic action in heart, lung, kidney tissue
  • Activates RXFP1 receptor via cGMP signaling arm
  • Vasodilatory effects
  • May support tissue remodeling and scar prevention
  • Reduces collagen deposition in injury models

ARA-290 (Cibinetide) side effects

  • Generally well-tolerated in clinical trials
  • Injection-site reactions (mild)
  • No erythropoietic effects (deliberate design)
  • Long-term safety with chronic dosing still being characterized

B7-33 side effects

  • Human safety data essentially absent
  • Theoretical: hypotension from vasodilation
  • Injection-site reactions
  • Possible effect on uterine / cervical tissue (relaxin family)

ARA-290 (Cibinetide) dosing ranges

Small-fiber neuropathy / nerve healing

2-8 mg · Once daily (SubQ) · 4-12 weeks per cycle

General tissue protection research

1-4 mg · Daily or alternate-day · Per research protocol

B7-33 dosing ranges

Research / anti-fibrotic

1-2 mg · Daily (SubQ or IV in preclinical work) · Per research protocol

Full ARA-290 (Cibinetide) guide → Full B7-33 guide →

ARA-290 (Cibinetide) vs B7-33 — common questions

What is the difference between ARA-290 (Cibinetide) and B7-33?

ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. B7-33: Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity. Typical dose 1000-2000 mcg. Both fall under the Healing & Recovery and Muscle Growth categories.

Can you stack ARA-290 (Cibinetide) and B7-33?

Stacking ARA-290 (Cibinetide) with B7-33 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ARA-290 (Cibinetide) or B7-33?

ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. B7-33 is typically dosed: Daily (SubQ or IV in preclinical work) for Research / anti-fibrotic.

Are ARA-290 (Cibinetide) and B7-33 FDA approved?

ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. B7-33: Not FDA approved.

Related peptide comparisons

ara-290 vs bpc-157ara-290 vs kpvara-290 vs tb-500ara-290 vs tb-500-frag-17-23ara-290 vs vipace-031 vs b7-33

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free